Scarica l'app Stockscreener
8.66
0.81%
0.07
Dopo l'orario di chiusura:
8.61
-0.05
-0.58%
Precedente Chiudi:
$8.59
Aprire:
$8.6
Volume 24 ore:
841.67K
Relative Volume:
0.68
Capitalizzazione di mercato:
$679.39M
Reddito:
$400.05M
Utile/perdita netta:
$181.01M
Rapporto P/E:
4.1252
EPS:
2.0993
Flusso di cassa netto:
$194.71M
1 W Prestazione:
+0.12%
1M Prestazione:
+14.70%
6M Prestazione:
-24.30%
1 anno Prestazione:
-39.61%
Intervallo 1D:
$8.46
$8.695
Intervallo di 1 settimana:
$8.46
$9.0851
Portata 52W:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Nome
CorMedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.66 | 673.90M | 400.05M | 181.01M | 194.71M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Leerink Partners | Outperform |
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-02-17 | Iniziato | Needham | Buy |
| 2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-09-21 | Iniziato | Truist | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2019-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2018-12-06 | Iniziato | ROTH Capital | Buy |
| 2017-09-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
| 2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
| 2016-11-11 | Reiterato | FBR & Co. | Outperform |
| 2016-03-17 | Reiterato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | FBR Capital | Outperform |
| 2015-11-16 | Reiterato | ROTH Capital | Neutral |
| 2015-10-29 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Reiterato | ROTH Capital | Buy |
| 2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
CorMedix Inc Borsa (CRMD) Ultime notizie
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath MomentumLearn Why - Yahoo Finance
CorMedix Inc. (CRMD) Reports Q1 2026 Results - Insider Monkey
CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake - Stock Titan
CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake - Stock Titan
5 Most Profitable Small Cap Stocks to Buy - Insider Monkey
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
CRMD Q1 2026 Earnings: EPS Beat of 31.72% Drives Stock HigherProfit Recovery Report - newsline.com
Federal appeals court upholds CorMedix patent win over Nexus - Investing.com UK
Federal Circuit Affirms CorMedix Patent Victory, Blocking Nexus Generic MINOCIN® Launch Until Patent Expiration 1 - minichart.com.sg
Federal appeals court upholds CorMedix patent win over Nexus By Investing.com - Investing.com South Africa
Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN® patents and injunction - Stock Titan
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation - Yahoo Finance
Can CorMedix Turn Launch Execution Into Momentum? - Kalkine Media
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CRMD Q1 2026 Earnings: Strong EPS Beat Drives Stock HigherPost-Earnings Drift - newsline.com
CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN
CRMD Technical Analysis | Trend, Signals & Chart Patterns | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD Q1 2026 Earnings: Strong EPS Beat as Company Advances Commercial EffortsNet Profit Margin - newsline.com
Avoiding Lag: Real-Time Signals in (CRMD) Movement - Stock Traders Daily
CRMD Q1 2026 Earnings: Positive EPS Surprise Despite Absence of RevenueGross Profit Margin - The Legal Advocate
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run - Seeking Alpha
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN
CorMedix Q1 earnings call highlights - MSN
CorMedix (CRMD) Tests Support Zone After Modest DeclineFade Trade - newsline.com
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView
CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - MarketBeat
CorMedix stock jumps as DefenCath fuels Q1 beat, 2026 outlook raised - MSN
Cormedix Earnings Call Highlights Surging Growth, New Risks - TipRanks
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD - MarketBeat
Needham Maintains CorMedix (CRMD) Buy Recommendation - MSN
Discipline and Rules-Based Execution in CRMD Response - Stock Traders Daily
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance
CorMedix Inc $CRMD Shares Bought by Vanguard Group Inc. - MarketBeat
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD) - The Globe and Mail
CorMedix (CRMD) Q1 earnings and revenues beat estimates - MSN
CorMedix Inc.Common Stock (NQ: CRMD - The Chronicle-Journal
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - The Globe and Mail
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership - Stock Titan
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - marketscreener.com
CorMedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):